Skip to main content

Month: April 2025

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

More than half say genetic testing for mental health medications could reduce concerns SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) — Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet concerns about potential side effects remain a significant barrier, preventing more than half (52%) from taking medication, according to the latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine. The majority of these patients (54%) agree that genetic testing for mental health medications (known as pharmacogenomic or PGx testing) could reduce these concerns. “It’s encouraging to see patients recognize what we, as healthcare providers,...

Continue reading

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Citizens Life Sciences Conference in New York City. Citizens Life Sciences Conference, May 7-8, 2025Event details:Date: Wednesday, May 7, 2025Time: 3:00 pm ETLocation: New York Hilton Midtown, New York Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation...

Continue reading

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers NAARDEN, the Netherlands and MIAMI, April 30, 2025 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced it will present new clinical and preclinical data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the European Atherosclerosis Society (EAS) 93rd Congress, taking place on May...

Continue reading

Westwood Celebrates One-Year Anniversary of Westwood Salient Enhanced Energy Income ETF (NYSE: WEEI)

WEEI Marks a Successful First Year with a 11.9% Annualized Distribution Rate (distributed monthly) and Growing Investor Demand DALLAS, April 30, 2025 (GLOBE NEWSWIRE) — Westwood Holdings Group (NYSE: WHG), a boutique asset management, trust and wealth services firm, is pleased to celebrate the one-year anniversary of the Westwood Salient Enhanced Energy Income ETF (NYSE: WEEI) (“WEEI” or the “Fund”). Since its launch, WEEI has gained strong traction among income-seeking investors, delivering on its objective of providing a steady stream of income with an annualized distribution rate of 11.9%1 as of March 28, 2025. WEEI is designed to offer investors exposure to the energy sector seeking to provide enhanced income through its covered-call strategy. We believe this approach allows investors to participate in the strong cash flow...

Continue reading

Vertex Announces Strategic Investment in AI Tax Compliance Startup Kintsugi

KING OF PRUSSIA, Pa., April 30, 2025 (GLOBE NEWSWIRE) — Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a global provider of indirect tax technology solutions, today announced it has completed a strategic investment in Kintsugi, a San Francisco-based, AI-native startup focused on automating sales tax compliance for small and mid-size businesses (SMBs). Terms of the agreement include a $15 million minority investment representing a 10 percent ownership interest, as well as IP sharing and a commercial arrangement. Additionally, Vertex will join the Kintsugi Board of Directors. The adoption of tax automation solutions is growing substantially as businesses face increasing compliance complexity associated with eCommerce and SaaS growth, cross-border trade and a patchwork of new tax regulations. Kintsugi automates the entire...

Continue reading

Safe Harbor Financial Expands Executive Leadership Team with Appointments of Jeffrey Kay as SVP of Marketing and Dominic Marella as VP of Business Development

Company Strengthens Strategic Growth Initiatives with Cannabis Industry Veterans GOLDEN, Colo., April 30, 2025 (GLOBE NEWSWIRE) — SHF Holdings, Inc., d/b/a Safe Harbor Financial (“Safe Harbor” or the “Company”) (Nasdaq: SHFS), a fintech leader providing financial services and credit facilities to the regulated cannabis industry, announced two strategic appointments to its leadership team: Jeffrey Kay as senior vice president of Marketing and the return of Dominic Marella as vice president of Business Development. Together, Kay and Marella will play key roles in expanding Safe Harbor’s national footprint, enhancing client services and elevating brand visibility—supporting the Company’s mission to deliver compliant, scalable and technology-driven financial solutions to cannabis-related businesses (CRBs). “Safe Harbor is entering...

Continue reading

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7

DUBLIN, Ireland, April 30, 2025 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Wednesday, May 7, 2025, to provide a corporate update and discuss the Company’s financial results for the first quarter ended March 31, 2025. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. About Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc (Nasdaq: AVDL)...

Continue reading

Kestra Medical Technologies to Participate in Upcoming Investor Conferences

KIRKLAND, Wash., April 30, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, is scheduled to participate in the following upcoming investor conferences: Event: BofA Securities 2025 Health Care ConferenceDate: Wednesday, May 14Presentation time: 6:40 p.m. ET Event: Goldman Sachs 46th Annual Global Healthcare Conference 2025Date: Wednesday, June 11Presentation time: 8:00 a.m. ET Interested parties may access a live webcast and replay of each presentation by visiting the Kestra Medical Technologies investor relations website. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention...

Continue reading

LeddarTech to Announce Second Quarter 2025 Financial Results and Host Investor and Business Update Call on May 14, 2025

QUEBEC CITY, April 30, 2025 (GLOBE NEWSWIRE) — LeddarTech® Holdings Inc. (“LeddarTech”) (Nasdaq: LDTC), an automotive software company that provides patented disruptive AI-powered low-level sensor fusion and perception software technology, LeddarVision™, for ADAS, AD and parking applications, announced today that it plans to release its second quarter 2025 financial results before the market opens on Wednesday, May 14, 2025. It will host an Investor and Business Update conference call and webcast on the same day at 8:00 a.m. ET. Frantz Saintellemy, President and Chief Executive Officer, and Chris Stewart, Chief Financial Officer, will be participating in the call. The conference call can be accessed in the U.S. by dialing (646) 307-1963 and via (800) 715-9871 for international callers. The conference ID is 1293674. Interested...

Continue reading

INNEOVA Holdings Limited Strengthens Engineering Capabilities and Accelerates Growth in Sustainable Solutions with the Acquisition of INNEOVA Engineering Pte. Ltd.

SINGAPORE, April 30, 2025 (GLOBE NEWSWIRE) — INNEOVA Holdings Limited (Nasdaq: INEO, “INNEOVA Holdings” or the “Company” or the “Group”), a leading Singapore-based provider of high-quality Original Equipment Manufacturer (“OEM”), third-party branded and in-house branded replacement parts for motor vehicles and non-vehicle combustion engines, today announced that it has completed the acquisition of INNEOVA Engineering Pte. Ltd. (“INNEOVA Engineering”), a Singapore-based engineering solutions provider. This strategic acquisition represents a significant milestone in INNEOVA Holdings’ transformation strategy, following the Company’s recent corporate rebranding from SAG Holdings Limited to INNEOVA Holdings Limited. The acquisition strengthens the Company’s...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.